The firm is preparing for a trial to show the efficacy of its CyPath Lung test and support a submission to the US Food and Drug Administration for marketing clearance.

The firm said that a strong start to the commercialization of its Liaison Plex platform also aided growth in its molecular diagnostics business.

To address the continuously evolving methods of cyberattacks, DGQEX has implemented several cutting-edge on-chain security ...

PNC Financial Services Group Inc. raised its position in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 21.5% in the fourth ...

Some of the world’s most advanced AI systems struggle to tell the time, a study says. Originally published on talker.news, ...